HC Wainwright Starts Coverage of Coherus and Agios at Buy
HC Wainwright initiated coverage of Coherus Oncology and Agios Pharmaceuticals, both rated Buy, with price targets of $7 and $55 per share, respectively.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
HC Wainwright & Co. has started coverage of Coherus Oncology with a Buy rating and a $7 price target. According to TradingView, that target works out to roughly 503.4% above the October 28 close of $1.16.
The same firm also began coverage of Agios Pharmaceuticals with a Buy rating and a $55 target. TradingView, citing Benzinga data, puts the potential gain at 44.3% from the October 28 close of $38.12.
why it matters
Initiations with a Buy rating are routine analyst actions, and this one covers two small biotech names rather than a broad market. Price targets reflect the analyst's own estimate and are not forecasts of where shares will trade.
tags
instruments
sources
- HC Wainwright & Co. assumes coverage of Coherus Oncology at Buy, sets price target at $7 — TradingView, 29 October 2026 at 13:17 UTC
- HC Wainwright & Co. assumes coverage of Agios Pharmaceuticals at Buy, sets price target at $55 — TradingView, 29 October 2026 at 13:15 UTC
- Coherus Oncology Price Target Announced at $7.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 29 October 2026 at 13:28 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗